sim0270
mAbexperimentalADC
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jul 23, 2024 (NCT06536036)
Timeline
Indications
Mechanism of action
TACSTD2 inhibitor
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06680921 | Phase 3 | Feb 28, 2025 | Government of China, Simcere Pharmaceutical Co., Ltd |
| NCT06654791 | Phase 1 | Oct 17, 2024 | Government of China, Simcere Pharmaceutical Co., Ltd |
| NCT06536036 | Phase 1 | Jul 23, 2024 | Government of China, Simcere Pharmaceutical Co., Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 3 | 0 | 2 | 2024 |
| Simcere Pharmaceutical Co., Ltd | For profit | 3 | 3 | 2 | 2024 |
2 organizations
Page 1 / 1